EUVIMEDEUVIMED entdecken
Crossref

Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan

Alam Zeb, Moath Ahmed Abdullah Almuradi, Inam Ullah Khan, Mohammad Haroon

Pakistan Journal of Medical Sciences · 19.11.2026 · 42 (12) · 3352-3357

DOI: 10.12669/pjms.42.12.16136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Medical Sciences, online erschienen am 19.11.2026. Verfasst von Alam Zeb und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effectiveness, tolerability, and safety profile of tofacitinib in patients with rheumatoid arthritis. Methodology: A retrospective observational cohort study using routine clinical records from May 2, 2023 to December 31, 2025. Adults meeting the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria were included. Effectiveness was assessed by change in DAS28 disease activity category and by remission or low disease activity at follow-up. Paired category changes used Wilcoxon signed-rank and marginal homogeneity tests. Logistic regression examined predictors of remission.

Results

The cohort included 319 patients, mean age 41.23 ± 12.40 years, 71.8% women. Baseline disease activity was high in 87.1% and moderate in 12.9%, with no remission. At follow-up, 47.0% achieved remission and 36.7% achieved low disease activity, while high activity fell to 6.3% with p less than 0.001. Male sex showed lower odds of remission with adjusted odds ratio 0.599 and 95% confidence interval 0.362 to 0.990. Adverse events were documented in 9.4%. Treatment was recorded as well tolerated in 93.7%, and 15.7% discontinued. Common events were raised ALT 6.3%, lipid abnormalities 3.1%, and herpes zoster 3.1%. Myocardial infarction 1.3% and thrombosis 0.9% were rare.

Conclusion

In this tertiary-care cohort, tofacitinib was linked to a large shift toward remission or low disease activity with a manageable recorded safety profile. Use requires baseline risk review and follow-up monitoring.

Zitieren

APA

Zeb, A., Almuradi, M. A. A., Khan, I. U., & Haroon, M. (2026). Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan. Pakistan Journal of Medical Sciences, 42(12), 3352-3357. https://doi.org/10.12669/pjms.42.12.16136

Vancouver

Zeb A, Almuradi MAA, Khan IU, Haroon M. Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan. Pakistan Journal of Medical Sciences. 2026;42(12):3352-3357. doi:10.12669/pjms.42.12.16136

BibTeX
@article{Zeb2026,
  author = {Zeb, Alam and Almuradi, Moath Ahmed Abdullah and Khan, Inam Ullah and Haroon, Mohammad},
  title = {Efficacy, tolerability, and adverse events of tofacitinib in rheumatoid arthritis: A real-world study at Khyber Teaching Hospital, Peshawar, Pakistan},
  journal = {Pakistan Journal of Medical Sciences},
  year = {2026},
  volume = {42},
  number = {12},
  pages = {3352--3357},
  doi = {10.12669/pjms.42.12.16136}
}
Kostenlos starten →